Nilar Lwin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nilar Lwin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A. Bannan
Department of Medicine, Port Macquarie Base Hospital, NSW, 2444, Australia; UNSW Medicine Phase 2 Convener Rural Clinical School, Port Macquarie, NSW, 2444, Australia
1 shared publicationClaire Johnston
Port Macquarie Base Hospital (PMBH) Port Macquarie New South Wales Australia
1 shared publication- Jennifer H. Martin
Chair of Clinical Pharmacology School of Medicine and Public Health, University of Newcastle Newcastle Australia
1 shared publication Jenny Burgess
Port Macquarie Base Hospital (PMBH) Port Macquarie New South Wales Australia
1 shared publication- Ji Woong Yoo
Clinical Pharmacology, University of Newcastle
1 shared publication - Joshua Saul Davis
School of Medicine and Public Health, University of Newcastle
1 shared publication
Latest Publications
- 1 November 2020
- Published by Elsevier in Infection, Disease & Health
- Vol. 25 (4) , 245-252
A retrospective observational study on enterococcal bacteraemia and endocarditis at a regional hospital in New South Wales, Australia
- 1 November 2020
- Published by Elsevier in Infection, Disease & Health
- Vol. 25 (4) , 245-252
A retrospective observational study on enterococcal bacteraemia and endocarditis at a regional hospital in New South Wales, Australia
- Open Access
- 18 September 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 50 (10) , 1271-1273
Hospital‐in‐the‐Home experience of first 23 COVID‐19 patients at a regional NSW hospital
Ambulatory care is an important service for patients with the COVID‐19 infection especially in a regional area where most of the patients underwent home isolation. Escalation of treatment and timely transition to inpatient care are critical when COVID‐19 patients deteriorate. Equally important is ensuring transfer into facility is carried out in a well‐planned, safe manner to prevent exposure to health care professionals as well as other inpatients. This study is a summary of our COVID Hospital‐in‐the‐Home (HITH) service and clinical presentation of COVID‐19 patients.
- 18 September 2020
- Published by Wiley in Internal Medicine Journal
- Vol. 50 (10) , 1271-1273
Open AccessHospital‐in‐the‐Home experience of first 23 COVID‐19 patients at a regional NSW hospital
Ambulatory care is an important service for patients with the COVID‐19 infection especially in a regional area where most of the patients underwent home isolation. Escalation of treatment and timely transition to inpatient care are critical when COVID‐19 patients deteriorate. Equally important is ensuring transfer into facility is carried out in a well‐planned, safe manner to prevent exposure to health care professionals as well as other inpatients. This study is a summary of our COVID Hospital‐in‐the‐Home (HITH) service and clinical presentation of COVID‐19 patients.
- 7 August 2019
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 1 (10) , 742-744
Flucloxacillin Drug-Level Samplings from Central Line Catheter Versus Peripheral Veins
- 7 August 2019
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 1 (10) , 742-744
Flucloxacillin Drug-Level Samplings from Central Line Catheter Versus Peripheral Veins
- Open Access
Estimation of Pharmacokinetic Parameters of Continuous Intravenous Flucloxacillin infusion in the Outpatient Settings (PKFLUCLOX)
Flucloxacillin, a beta-lactam antibiotic of the penicillin class, is considered first line therapy for methicillin sensitive Staphylococcus aureus (MSSA) in Australia. At our tertiary referral hospital in the home (HITH) program, it has been prescribed in a standard dosage of 8 grams per day by continuous infusion for more than 20 years. The aim of this observational study was to characterize the pharmacokinetic profile of flucloxacillin in patients who receive continuous infusion in the HITH setting, and to undertake population pharmacokinetic analysis performed with NONMEM software by comparing various structural models. This study utilised flucloxacillin concentrations from 44 separate specimens obtained from 23 patients. Twenty-five of these were collected immediately after elastomeric device removal, representing steady-state concentrations, and the remaining 19 were each collected at least 45 minutes after device removal to determine clearance of the drug. Plasma concentrations ranged from 13 to 194 mg/L with median steady-state concentration of 51.5 mg/L and inter-quartile range of 24.6 mg/L. The time-course of flucloxacillin was best described by a 1-compartment model. The best three covariates, CrCL (ΔOFV= -11.7), eGFR (ΔOFV= -5.9) and serum albumin (ΔOFV= -5.8) were found to be equivalent in terms of decreasing the OFV. CrCL was superior in explaining inter individual variability. The best model for flucloxacillin clearance was a one compartment model with CrCL as the sole covariate. The estimated population parameters were 9.5 L for volume of distribution and 8.1 L/h for flucloxacillin clearance.
Open AccessEstimation of Pharmacokinetic Parameters of Continuous Intravenous Flucloxacillin infusion in the Outpatient Settings (PKFLUCLOX)
Flucloxacillin, a beta-lactam antibiotic of the penicillin class, is considered first line therapy for methicillin sensitive Staphylococcus aureus (MSSA) in Australia. At our tertiary referral hospital in the home (HITH) program, it has been prescribed in a standard dosage of 8 grams per day by continuous infusion for more than 20 years. The aim of this observational study was to characterize the pharmacokinetic profile of flucloxacillin in patients who receive continuous infusion in the HITH setting, and to undertake population pharmacokinetic analysis performed with NONMEM software by comparing various structural models. This study utilised flucloxacillin concentrations from 44 separate specimens obtained from 23 patients. Twenty-five of these were collected immediately after elastomeric device removal, representing steady-state concentrations, and the remaining 19 were each collected at least 45 minutes after device removal to determine clearance of the drug. Plasma concentrations ranged from 13 to 194 mg/L with median steady-state concentration of 51.5 mg/L and inter-quartile range of 24.6 mg/L. The time-course of flucloxacillin was best described by a 1-compartment model. The best three covariates, CrCL (ΔOFV= -11.7), eGFR (ΔOFV= -5.9) and serum albumin (ΔOFV= -5.8) were found to be equivalent in terms of decreasing the OFV. CrCL was superior in explaining inter individual variability. The best model for flucloxacillin clearance was a one compartment model with CrCL as the sole covariate. The estimated population parameters were 9.5 L for volume of distribution and 8.1 L/h for flucloxacillin clearance.
- Open Access
- 30 January 2018
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 5 (2) , ofy027
Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection
Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.
- 30 January 2018
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 5 (2) , ofy027
Open AccessAdalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection
Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.